Brief: Glenmark Pharma Receives EIR From US FDA For Monroe Facility
27/11/2025 04:46
Nov 27 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK PHARMA - RECEIVES EIR FROM U.S. FDA FOR MONROE FACILITY GLENMARK PHARMA - TO RESTART COMMERCIAL MANUFACTURING AT MONROE FACILITY Source text: ID:nNSEbbsh39 Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter